These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 4950404)

  • 1. Pharmacology and pathophysiology of dopaminergic neurons.
    Hornykiewicz O
    Adv Cytopharmacol; 1971 May; 1():369-77. PubMed ID: 4950404
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings: Differentiation between neuroleptic antipsychotic properties and side effects by subgroups of dopaminergic neurons.
    Bunney BS; Aghajanian GK
    Psychopharmacol Bull; 1974 Oct; 10(4):17-8. PubMed ID: 4473793
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathophysiology of schizophrenia and the striatum.
    Klawans HL; Goetz C; Westheimer R
    Dis Nerv Syst; 1972 Nov; 33(11):711-9. PubMed ID: 4266033
    [No Abstract]   [Full Text] [Related]  

  • 4. [The antipsychotic action of neuroleptics and basal ganglia function].
    Arushanian EB
    Farmakol Toksikol; 1973; 26(4):481-9. PubMed ID: 4151298
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity.
    Bunney BS; Walters JR; Roth RH; Aghajanian GK
    J Pharmacol Exp Ther; 1973 Jun; 185(3):560-71. PubMed ID: 4576427
    [No Abstract]   [Full Text] [Related]  

  • 6. [Late irreversible extrapyramidal syndrome following neuroleptic use].
    Boucebci M
    Acta Psychiatr Belg; 1972 Mar; 72(2):233-40. PubMed ID: 5056017
    [No Abstract]   [Full Text] [Related]  

  • 7. Antagonism by neuroleptics of abnormal behavior induced by activation of brain dopamine receptors.
    Van Rossum JM
    Mod Probl Pharmacopsychiatry; 1970; 5():65-7. PubMed ID: 5527171
    [No Abstract]   [Full Text] [Related]  

  • 8. [Biogenic amines and schizophrenia].
    Schöpf J
    Schweiz Med Wochenschr; 1975 Sep; 105(38):1201-9. PubMed ID: 1061994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Akathisia: a side effect to be remembered.
    Raskin DE
    Am J Psychiatry; 1972 Sep; 129(3):345-7. PubMed ID: 5053718
    [No Abstract]   [Full Text] [Related]  

  • 10. A dopaminergic-cholinergic mechanism in production of psychotic symptoms.
    Friedhoff AJ; Alpert M
    Biol Psychiatry; 1973 Apr; 6(2):165-9. PubMed ID: 4709131
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
    Yasuhara T; Shingo T; Kobayashi K; Takeuchi A; Yano A; Muraoka K; Matsui T; Miyoshi Y; Hamada H; Date I
    Eur J Neurosci; 2004 Mar; 19(6):1494-504. PubMed ID: 15066146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurotransmitters systems interactions in cat brain in the control of emotional-defensive behavior.
    Romaniuk A
    Acta Physiol Pol; 1980; 31 Suppl 20():107-17. PubMed ID: 6105759
    [No Abstract]   [Full Text] [Related]  

  • 14. The pharmacology of tardive dyskinesias.
    Klawans HL
    Am J Psychiatry; 1973 Jan; 130(1):82-6. PubMed ID: 4264755
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopamine and extrapyramidal motor function and dysfunction.
    Hornykiewicz O
    Res Publ Assoc Res Nerv Ment Dis; 1972; 50():390-415. PubMed ID: 4561070
    [No Abstract]   [Full Text] [Related]  

  • 16. Two types of dopamine receptors in behavioral regulation.
    van Rossum JM
    Fed Proc; 1978 Aug; 37(10):2415-21. PubMed ID: 354975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesias.
    Rubovits R; Klawans HL
    Arch Gen Psychiatry; 1972 Oct; 27(4):502-7. PubMed ID: 5072718
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: Delayed drug-induced dystonias.
    Br Med J; 1973 Nov; 4(5889):424. PubMed ID: 4749799
    [No Abstract]   [Full Text] [Related]  

  • 19. Rational use of psychotropic drugs. III. Major tranquilizers.
    Greenblatt DJ; Shader RI
    Am J Hosp Pharm; 1974 Dec; 31(12):1226-31. PubMed ID: 4156455
    [No Abstract]   [Full Text] [Related]  

  • 20. Toward hypotheses for a biochemical component in the vulnerability to schizophrenia.
    Kety SS
    Semin Psychiatry; 1972 Aug; 4(3):233-8. PubMed ID: 4155537
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.